Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

325.62 +12.90 (+4.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Eli Lilly Inks Another RNA Collab, This Time With ProQR
Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR... 
Via Benzinga
This Med Tech Innovator Just Doubled, And It Can Do It Again
We’re here to crush the market with the foremost innovative tech leaders. 
Via Talk Markets
Abbott Labs Stock Strength Rises Into New Percentile As Health Care Giant Expands Organically And Via Acquisition
Additionally, Chicago-based Abbott Labs stock carries a near-perfect 98 Composite Rating, putting it in the top 2% of all stocks. 
Via Investor's Business Daily
Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition... 
Via Benzinga
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR... 
Via Benzinga
Exposures Product Safety
Where Eli Lilly Stands With Analysts
Analysts have provided the following ratings for Eli Lilly (NYSE:LLY) within ... 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly
AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq. 
Via Investor's Business Daily
Exposures Product Safety
Market Briefing For Wednesday, Sept. 1
Nuances and ambiguities dominate the market and even geopolitical scene at the moment. We are going to have hotter inflation than the Fed would like, but growth does matter, because we concurrently... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential
Mayo Clinic and nference are jointly conducting artificial intelligence-powered studies evaluating monoclonal antibodies for COVID-19 in patients with an elevated risk... 
Via Benzinga
Exposures COVID-19
A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the S&P and the Nasdaq hit record closing highs in the previous session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies
After the US paused distribution of Eli Lilly And Co's COVID-19 antibody therapies in June, the pharmaceutical company says those therapies are once again being distributed. 
Via Talk Markets
Exposures COVID-19
Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies
After the US paused distribution of Eli Lilly And Co (NYSE: LLY)'s COVID-19 antibody therapies in June, the pharmaceutical company says those therapies are once again being... 
Via Benzinga
Exposures COVID-19
Here's What This Label Expansion Could Mean for Eli Lilly Investors
The pharmaceutical company's type 2 diabetes drug Jardiance was recently approved by the FDA for another indication. 
Via The Motley Fool
Exposures Product Safety
Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field
Eli Lilly And Co (NYSE: LLY) and Boehringer Ingelheim have rolled out full results of EMPEROR-Preserved phase 3 trial of Jardiance (empagliflozin) for heart... 
Via Benzinga
This Potential Indication Could Mean Profit for Eli Lilly Investors
Eli Lilly updated investors on its ongoing phase 3 trials to treat patients who have moderate to severe eczema with a new drug. 
Via The Motley Fool
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
The second-quarter earnings season was a strong one for the drug/biotech sector. 
Via Talk Markets
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
Friday Fears and Other Stock News Updates
Toyota has cut its output 40% over fear of the Delta variant of Covid, plus shortages of electronics. This is terrifying markets outside the USA. And other global stock news updates. 
Via Talk Markets
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,... 
Via Benzinga
Exposures Product Safety
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
FDA Approves Eli Lilly's Jardiance For Heart Failure
The FDA approves Eli Lilly And Co (NYSE: LLY) - Boehringer Ingelheim's Jardiance (empagliflozin) 10 mg for heart failure. The approval comes to... 
Via Benzinga
Exposures Product Safety
Eli Lilly Stock Soars To 96 Composite Rating
Eli Lilly saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 94 the day before. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
The 
Via Benzinga
Exposures Product Safety
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Innovent Biologics Inc (OTC: IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall... 
Via Benzinga
Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials
Eli Lilly And Co's (NYSE: LLY) lebrikizumab ADvocate 1 and ADvocate 2 Phase 3 clinical trials met primary and all key secondary endpoints at Week 16. ... 
Via Benzinga
Why AbCellera Biologics Stock Was Up More Than 17% on Friday
The biopharma company's second quarter was better than expected. The future looks pretty bright, too. 
Via The Motley Fool
Vaccine Stocks Fly On Booster Shot OK, But Their Run Could Be Short-Lived
Vaccine stocks popped Friday after the FDA authorized a third dose of their Covid shots from some immunocompromised people. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.